World's Best Scientists 2026 revealed!
Wilson H. Miller

Wilson H. Miller

D-Index & Metrics

Medicine

D-Index
91
Citations
54470
World Ranking
11502
National Ranking
464

Overview

Wilson H. Miller is affiliated with McGill University in Canada and has contributed extensively to the fields of Medicine, particularly within Oncology and Molecular Biology. Their research spans a variety of subfields including Immunology, Pulmonary and Respiratory Medicine, and Pathology and Forensic Medicine, reflecting a multidisciplinary approach to biomedical science.

Their body of work is notably concentrated on topics such as Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, CAR-T cell therapy research, Genetic factors in colorectal cancer, Colorectal Cancer Treatments and Studies, Immunotherapy and Immune Responses, and Immune Cell Function and Interaction.

Wilson H. Miller's research has appeared in a range of journals, with frequent publications in the Journal of Clinical Oncology, bioRxiv (Cold Spring Harbor Laboratory), Annals of Oncology, Journal for ImmunoTherapy of Cancer, and Clinical Cancer Research. These venues highlight their focus on clinical and translational cancer research and immunotherapy.

Recent notable papers authored or co-authored by Wilson H. Miller include:

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study (2020, The Lancet Oncology)
  • A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future (2020, Current Oncology)
  • Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study (2022, Journal of Clinical Oncology)
  • Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study (2022, Annals of Oncology)
  • Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial (2023, Nature Medicine)

Wilson H. Miller has collaborated frequently with a group of co-authors, which includes Sonia V. del Rincón, Christophe Gonçalves, Fan Huang, Natascha Gagnon, and Arielle Elkrief.

Best Publications

  • Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day

  • Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

    Axel Hauschild;Jean Jacques Grob;Lev V. Demidov;Thomas Jouary

  • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

    Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi

  • Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

    Robert H.I. Andtbacka;Howard L. Kaufman;Frances Collichio;Thomas Amatruda

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

    Aurélien Marabelle;Marwan Fakih;Juanita Lopez;Manisha Shah

  • Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Konstantin Penkov;John Haanen;Brian Rini

  • Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML

    A. Kakizuka;W.H. Miller;K. Umesono;K. Umesono;R.P. Warrell

  • Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).

    Raymond P. Warrell;Stanley R. Frankel;Wilson H. Miller;David A. Scheinberg

  • Role of the histone deacetylase complex in acute promyelocytic leukaemia

    Richard J. Lin;Richard J. Lin;Richard J. Lin;Laszlo Nagy;Laszlo Nagy;Satoshi Inoue;Wenlin Shao

  • Mechanisms of action of arsenic trioxide.

    Wilson H. Miller;Hyman M. Schipper;Janet S. Lee;Jack Singer

  • Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL) : I. As2O3 exerts dose-dependent dual effects on APL cells

    Guo-Qiang Chen;Xue-Geng Shi;Wei Tang;Shu-Min Xiong

  • A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein

    Jacqueline A. Dyck;Jacqueline A. Dyck;Gerd G. Maul;Wilson H. Miller;J.Don Chen

  • A review of cancer immunotherapy: from the past, to the present, to the future.

    K. Esfahani;L. Roudaia;N. Buhlaiga;S.V. Del Rincon

  • Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia.

    Josephia Muindi;Stanley R. Frankel;Wilson H. Miller;Ann Jakubowski

  • Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

    Sandra P D'Angelo;James Larkin;Jeffrey A Sosman;Celeste Lebbé

  • Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.

    Jose Baselga;Larry Norton;Hideo Masui;Atanasio Pandiella

  • Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

    James Larkin;David Minor;Sandra D'Angelo;Bart Neyns

  • Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.

    Jordi Rodon;Jean Charles Soria;Raanan Berger;Wilson H. Miller

  • Phase I clinical trial of i.v. ascorbic acid in advanced malignancy

    L.J. Hoffer;M. Levine;S. Assouline;D. Melnychuk

  • Arsenic Trioxide as an Inducer of Apoptosis and Loss of PML/RARα Protein in Acute Promyelocytic Leukemia Cells

    W. Shao;M. Fanelli;F. F. Ferrara;R. Riccioni

Frequent Co-Authors

Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Georgina V. Long
Georgina V. Long University of Sydney
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Christian U. Blank
Christian U. Blank Antoni van Leeuwenhoek Hospital
Axel Hauschild
Axel Hauschild Kiel University
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Matteo S. Carlino
Matteo S. Carlino University of Sydney
Paul Lorigan
Paul Lorigan University of Manchester
Samuel Waxman
Samuel Waxman Icahn School of Medicine at Mount Sinai
Hyman M. Schipper
Hyman M. Schipper McGill University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For aspiring medical professionals looking to accelerate their education or career transition, online programs offer flexible pathways to a variety of in-demand roles. Many students pursuing Medicine in the USA consider alternative health degrees to gain experience or advance more quickly within the healthcare field. These flexible online qualifications can be an excellent stepping stone or complement to a traditional medical education.

Those interested in advanced nursing roles may want to explore the short dnp programs which enable practitioners to complete their doctorate in nursing practice at a faster pace. If balancing work and study is a concern, you can also review the easiest dnp programs designed for students seeking manageable coursework without sacrificing educational quality.

For quicker entry into the nursing workforce, fast track medical lpn programs allow you to become a Licensed Practical Nurse in less time. Additionally, for those interested in mental health, the psych np online programs can open the door to specialized nurse practitioner roles with both speed and convenience.

Best Scientists Citing Wilson H. Miller

Trending Scientists